Alzheimer’s disease has traditionally been explained by the buildup of amyloid plaques in the brain, but growing evidence suggests this theory does not fully account for the disease or lead to effective treatments. A metabolic perspective proposes that Alzheimer’s may instead be driven by brain insulin resistance, which disrupts neuronal energy metabolism—while the brain’s ability to use ketones as an alternative fuel remains intact, offering potential strategies for prevention and support.
Summary: For decades, Alzheimer’s disease has largely been understood through the lens of the amyloid plaque hypothesis, which proposes that sticky protein deposits in the brain trigger neurodegeneration and cognitive decline. In this Metabolic Classroom lecture, Ben explains why that theory is increasingly being questioned. He reviews the historical origins of the plaque hypothesis and the repeated failure of drugs designed to remove amyloid plaques to meaningfully improve patient outcomes. The controversy surrounding manipulated data in influential Alzheimer’s research further highlights the need for a new framework to better explain the disease.
Ben then presents a compelling alternative: Alzheimer’s disease as a metabolic disorder driven by brain insulin resistance. Drawing from mechanistic studies, epidemiological data, and genetic insights, he explains how impaired insulin signaling in the brain can disrupt neuronal energy metabolism, increase tau tangles, impair amyloid clearance, and ultimately contribute to neurodegeneration. This concept has led some researchers to refer to Alzheimer’s as “Type 3 diabetes.”
The lecture also explores a hopeful implication of this metabolic framework. While glucose metabolism is impaired in Alzheimer’s brains, research shows that the brain’s ability to use ketones remains intact. This suggests that strategies that improve insulin sensitivity or increase ketone availability—such as carbohydrate restriction, fasting, exercise, or exogenous ketones—may offer promising avenues for prevention or metabolic support.
13:26 As much as I loth to ever rely on epidemiology, when the epidemiology is in sync with the mechanism then you have a powerful data perspective.
summerizer
Plaques and paradigm
- Alzheimer’s entered the field as plaques and tangles, but plaque burden never aligned cleanly with who did and did not become demented.
- The amyloid cascade model became the field’s organizing idea, drove funding and drug development, and turned plaque removal into the main therapeutic goal.
- A landmark 2006 Aβ*56 paper became a central support for this view, and its later retraction exposed how much confidence had rested on fragile data.
- The drug record followed the same pattern: anti-amyloid programs removed plaques more readily than they restored cognition or halted decline.
Brain insulin resistance
- A stronger fit is that Alzheimer’s is a brain insulin-resistance disorder in which neurons lose efficient access to glucose even when glucose is abundant.
- In this model, impaired insulin and IGF signaling drives energy shortage, tau dysregulation, weaker amyloid clearance, synaptic failure, and cognitive loss.
- de la Monte’s work anchors the “type 3 diabetes” term by tying worsening Alzheimer pathology to worsening defects in brain insulin signaling.
- Population data move in the same direction: diabetes tracks with higher dementia risk, and worse glycaemic history tracks with worse risk.
APOE4 and mechanism
- APOE4 fits this metabolic model because it can trap the insulin receptor inside neurons, weakening insulin signaling before late-stage pathology arrives.
- That gives APOE4 a direct route to brain fuel failure, tau disruption, and weaker amyloid clearance.
Ketones and practice
- The crucial asymmetry is that glucose handling falls early, while ketone uptake remains intact in mild cognitive impairment and early Alzheimer’s disease.
- PET work and post-mortem gene-expression work move in the same direction: glycolytic machinery falls broadly, while much of the ketolytic machinery stays usable outside oligodendrocytes.
- That makes ketones a rescue fuel, which is why ketogenic diets, MCT-based interventions, and exogenous ketones sit at the center of this account.
- The practical conclusion is to protect metabolic health early, lower chronic hyperinsulinaemia, and give special attention to carbohydrate restriction or ketone-raising strategies when brain glucose use is failing.
References
- [00:46] Alzheimer's Disease Is Type 3 Diabetes—Evidence Reviewed — https://doi.org/10.1177/193229680800200619
- [03:02] Alzheimer's Disease: The Amyloid Cascade Hypothesis — https://doi.org/10.1126/science.1566067
- [04:00] Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly — https://doi.org/10.1001/archneur.65.11.1509
- [05:15] A specific amyloid-β protein assembly in the brain impairs memory — https://doi.org/10.1038/nature04533
- [06:30] Retraction Note: A specific amyloid-β protein assembly in the brain impairs memory — https://doi.org/10.1038/s41586-024-07691-8
- [10:41] Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? — https://doi.org/10.3233/JAD-2005-7107
- [11:23] Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine — https://doi.org/10.3233/JAD-2005-8304
- [14:04] Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies — https://doi.org/10.1111/jdi.12087
- [14:17] The relationship between diabetes and the dementia risk: a meta-analysis — https://doi.org/10.1186/s13098-024-01346-4
- [14:33] Diabetes mellitus and the risk of dementia — https://doi.org/10.1212/WNL.53.9.1937
- [14:46] Associations of glycaemia-related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: A systematic review and meta-analysis — https://doi.org/10.1111/dme.70123
- [15:09] Association between Age at Diagnosis of Type 2 Diabetes and Subsequent Risk of Dementia and Its Major Subtypes — https://doi.org/10.3390/jcm13154386
- [17:07] Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes — https://doi.org/10.1016/j.neuron.2017.09.003
- [23:36] Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease — https://doi.org/10.3389/fnmol.2016.00053
- [24:09] A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease — https://doi.org/10.1016/j.exger.2017.07.004
- [25:04] Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression — https://doi.org/10.1002/alz.12310
- [27:38] Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial — https://doi.org/10.1186/1743-7075-6-31
- [28:34] Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance — https://doi.org/10.1371/journal.pone.0144116